Therapeutic flag Cosmetic cross-reference

Artemisinin

CAS 63968-64-9

Artemisinin (CAS 63968-64-9) is a Phase 3 pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
15
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
1
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Artemisinin
CAS Number
63968-64-9
UNII
9RMU91N5K2
InChIKey
BLUAFEHZUWYNDE-NNWCWBAJSA-N
ChEMBL ID
CHEMBL269671
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural producttherapeutic flag
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3
Late-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL269671 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 15 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- IC50 6753.758563311688 nM 615 -
- IC50 2.718979586538462 ug.mL-1 208 -
- EC50 3839.3454117647057 nM 85 -
- AC50 29354.83870967742 nM 31 -
- MIC 57.95057894736842 ug.mL-1 19 -
- Potency 8481.441176470587 nM 17 -
- EC50 0.00795 ug.mL-1 4 -
- IC50 0.01125 uM well-1 4 -
- Ki 8919.75 nM 4 -
- GI50 11333.333333333334 nM 3 -
- Kd 340 nM 2 -
- IC50 0.66 equiv 1 -
- IC50 0.001 mg/cm3 1 -
- Kd 0.000024 1 -
Cytochrome P450 1A2
Enzyme
IC50 5.699 - Homo sapiens
SOURCE IUPHAR/BPS 7 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
- - 8.149999618530273 pIC50 22363211
- - 7.820000171661377 pIC50 22363211
- - 8.520000457763672 pIC50 22363211
- - 9.100000381469727 pIC50 22363211
- - 8.239999771118164 pIC50 22363211
- - 9.220000267028809 pIC50 22363211
- - 8.270000457763672 pIC50 22363211
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Artemisinin used for in pharmaceutical contexts?

Artemisinin (CAS 63968-64-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Artemisinin?

No adverse-event association or SIDER side-effect rows are rendered for Artemisinin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Artemisinin also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Artemisinin with EU status "permitted".

What clinical phase is Artemisinin in?

Artemisinin is rendered with ChEMBL max phase 3.

What bioactivity targets are documented for Artemisinin?

Artemisinin has 15 bioactivity rows in this page query. Rendered target entries include Cytochrome P450 1A2.